{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=28&state=Minnesota",
    "query": {
      "state": "Minnesota",
      "city": "Minneapolis",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 7864,
    "total_pages": 787,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=29&state=Minnesota&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=27&state=Minnesota&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T03:27:42.011Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05067478",
      "title": "Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Vibegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 403,
      "start_date": "2021-10-28",
      "completion_date": "2024-07-26",
      "has_results": false,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 64,
      "location_summary": "Homewood, Alabama • Phoenix, Arizona • Tempe, Arizona + 54 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05067478"
    },
    {
      "nct_id": "NCT01583985",
      "title": "Strategies for Prescribing Analgesics Comparative Effectiveness Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Back Pain",
        "Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Opioid-intensive prescribing strategy",
          "type": "OTHER"
        },
        {
          "name": "Opioid-avoidant prescribing strategy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 265,
      "start_date": "2013-06-01",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2019-03-06",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01583985"
    },
    {
      "nct_id": "NCT02947685",
      "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HER-2 Positive Breast Cancer",
        "Estrogen Receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "palbociclib",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance Foundation Trials, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 518,
      "start_date": "2017-06-21",
      "completion_date": "2030-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 35,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02947685"
    },
    {
      "nct_id": "NCT00358215",
      "title": "RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure",
        "Anemia",
        "Cardiovascular Disease",
        "Ventricular Dysfunction",
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Darbepoetin alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2278,
      "start_date": "2006-06-01",
      "completion_date": "2012-10-11",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 254,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00358215"
    },
    {
      "nct_id": "NCT02866435",
      "title": "Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Glucose",
          "type": "DRUG"
        },
        {
          "name": "Potassium phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2016-11",
      "completion_date": "2019-12-30",
      "has_results": false,
      "last_update_posted_date": "2021-02-01",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02866435"
    },
    {
      "nct_id": "NCT02798406",
      "title": "Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Cancer",
        "Brain Neoplasm",
        "Glioma",
        "Glioblastoma",
        "Gliosarcoma",
        "Malignant Brain Tumor",
        "Neoplasm, Neuroepithelial",
        "Neuroectodermal Tumors",
        "Neoplasm by Histologic Type",
        "Neoplasm, Nerve Tissue",
        "Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "DNX-2401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DNAtrix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2016-10-06",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02798406"
    },
    {
      "nct_id": "NCT03063749",
      "title": "RESOLUTE ONYX Post-Approval Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medtronic Vascular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 416,
      "start_date": "2017-03-30",
      "completion_date": "2022-08-18",
      "has_results": false,
      "last_update_posted_date": "2023-11-22",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 23,
      "location_summary": "Huntsville, Alabama • La Jolla, California • Riverside, California + 19 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03063749"
    },
    {
      "nct_id": "NCT04293185",
      "title": "A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "bb1111",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "2 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2020-02-14",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04293185"
    },
    {
      "nct_id": "NCT05534243",
      "title": "The ED-AWARENESS-2 Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Awareness",
        "Mechanical Ventilation",
        "Intubation Complication",
        "PTSD"
      ],
      "interventions": [
        {
          "name": "Standard neuromuscular blocker practices",
          "type": "OTHER"
        },
        {
          "name": "Education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3212,
      "start_date": "2023-06-28",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 4,
      "location_summary": "Iowa City, Iowa • Minneapolis, Minnesota • Camden, New Jersey + 1 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05534243"
    },
    {
      "nct_id": "NCT00677365",
      "title": "Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis (CF)"
      ],
      "interventions": [
        {
          "name": "MP-376",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2008-06",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-11-05T03:27:42.011Z",
      "location_count": 39,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00677365"
    }
  ]
}